publication venue for
- Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer.. 8. 2023
- Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma.. 7. 2022
- Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.. 6. 2021
- Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines.. 6. 2021
- Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort.. 6. 2021
- SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.. 6. 2021
- First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts.. 6. 2021
- Body weight and return to work among survivors of early-stage breast cancer.. 5. 2020
- Oncological care organisation during COVID-19 outbreak.. 5. 2020
- Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma.. 5. 2020
- Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial.. 6. 2021
- Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials. 2021
- 30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). 2018
- Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice. 2023
- The current role of precision surgery in oligometastatic prostate cancer. 2022
- ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. 2016